StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $9.00.

Aptose Biosciences Price Performance

Aptose Biosciences stock opened at $0.40 on Wednesday. The company has a market capitalization of $7.16 million, a PE ratio of -0.06 and a beta of 1.25. Aptose Biosciences has a one year low of $0.33 and a one year high of $3.45. The business has a 50 day simple moving average of $0.49 and a 200 day simple moving average of $0.95.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.15. Equities analysts anticipate that Aptose Biosciences will post -2.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.